Barrington G Burnett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4789846/publications.pdf

Version: 2024-02-01

39 papers	3,571 citations	236925 25 h-index	302126 39 g-index
40 all docs	40 docs citations	40 times ranked	4978 citing authors

#	Article	IF	Citations
1	Enabling the genomic revolution in Africa. Science, 2014, 344, 1346-1348.	12.6	361
2	Impaired Synaptic Vesicle Release and Immaturity of Neuromuscular Junctions in Spinal Muscular Atrophy Mice. Journal of Neuroscience, 2009, 29, 842-851.	3.6	344
3	The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Human Molecular Genetics, 2003, 12, 3195-3205.	2.9	341
4	Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. Journal of Clinical Investigation, 2007, 117, 659-671.	8.2	308
5	Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C. Nature Genetics, 2010, 42, 170-174.	21.4	278
6	MicroRNA Pathways Modulate Polyglutamine-Induced Neurodegeneration. Molecular Cell, 2006, 24, 157-163.	9.7	240
7	Regulation of SMN Protein Stability. Molecular and Cellular Biology, 2009, 29, 1107-1115.	2.3	234
8	Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Human Molecular Genetics, 2009, 18, 27-42.	2.9	171
9	The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4330-4335.	7.1	164
10	Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Human Molecular Genetics, 2007, 16, 1593-1603.	2.9	137
11	Cowchock Syndrome Is Associated with a Mutation in Apoptosis-Inducing Factor. American Journal of Human Genetics, 2012, 91, 1095-1102.	6.2	134
12	Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition. Annals of Neurology, 2008, 64, 465-470.	5.3	133
13	Hereditary Spastic Paraplegia Type 43 (SPG43) is Caused by Mutation inC19orf12. Human Mutation, 2013, 34, 1357-1360.	2.5	79
14	Survival motor neuron protein deficiency impairs myotube formation by altering myogenic gene expression and focal adhesion dynamics. Human Molecular Genetics, 2014, 23, 4745-4757.	2.9	66
15	Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Human Molecular Genetics, 2011, 20, 3667-3677.	2.9	64
16	Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice. Human Molecular Genetics, 2012, 21, 4448-4459.	2.9	56
17	Non-targeted Identification of Prions and Amyloid-forming Proteins from Yeast and Mammalian Cells. Journal of Biological Chemistry, 2013, 288, 27100-27111.	3.4	55
18	The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes the degradation of survival of motor neuron protein. Molecular Biology of the Cell, 2013, 24, 1863-1871.	2.1	50

#	Article	IF	Citations
19	The role of the immunoproteasome in interferon-Î³-mediated microglial activation. Scientific Reports, 2017, 7, 9365.	3.3	39
20	Expression of expanded polyglutamine targets profilin for degradation and alters actin dynamics. Neurobiology of Disease, 2008, 30, 365-374.	4.4	37
21	CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiology of Disease, 2016, 88, 118-124.	4.4	35
22	Exome sequencing identifies a novel TRPV4 mutation in a CMT2C family. Neurology, 2012, 79, 192-194.	1.1	34
23	Genetics of low spinal muscular atrophy carrier frequency in subâ€Saharan Africa. Annals of Neurology, 2014, 75, 525-532.	5.3	31
24	MiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy. Molecular Therapy, 2016, 24, 937-945.	8.2	29
25	Emerging treatment options for spinal muscular atrophy. Current Treatment Options in Neurology, 2009, 11, 90-101.	1.8	28
26	A candidate gene for autoimmune myasthenia gravis. Neurology, 2012, 79, 342-347.	1.1	21
27	Viral mediated knockdown of <scp>GATA6</scp> in <scp>SMA iPSC</scp>â€derived astrocytes prevents motor neuron loss and microglial activation. Glia, 2022, 70, 989-1004.	4.9	17
28	ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight, 2016, 1, e88427.	5.0	16
29	Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy. Journal of Medicinal Chemistry, 2017, 60, 4594-4610.	6.4	13
30	Survival motor neuron deficiency slows myoblast fusion through reduced myomaker and myomixer expression. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1098-1116.	7.3	11
31	SMN-deficiency disrupts SERCA2 expression and intracellular Ca2+ signaling in cardiomyocytes from SMA mice and patient-derived iPSCs. Skeletal Muscle, 2020, 10, 16.	4.2	9
32	Genetics and genomic medicine in Mali: challenges and future perspectives. Molecular Genetics & Genomic Medicine, 2016, 4, 126-134.	1.2	8
33	Survival motor neuron protein deficiency alters microglia reactivity. Glia, 2022, , .	4.9	7
34	A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein. Cell Reports, 2021, 35, 109125.	6.4	6
35	Targeting splicing in spinal muscular atrophy. Annals of Neurology, 2008, 63, 3-6.	5.3	5
36	Neurogenic and Myogenic Contributions to Hereditary Motor Neuron Disease. Neurodegenerative Diseases, 2012, 9, 199-209.	1.4	5

#	Article	IF	Citations
37	Does the survival motor neuron copy number variation play a role in the onset and severity of sporadic amyotrophic lateral sclerosis in Malians?. ENeurologicalSci, 2016, 3, 17-20.	1.3	2
38	A combinatorial approach increases SMN level in SMA model mice. Human Molecular Genetics, 2022, 31, 2989-3000.	2.9	2
39	Socio-cultural adaptation and standardization of Dubois' five words testing in a population of normal subject in Mali, West Africa. ENeurologicalSci, 2016, 3, 60-63.	1.3	1